Breaking News, Trials & Filings

OncoMed Begins NSCLC Trial

Early-stage trial tests MAb with docetaxel

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

OncoMed Pharmaceuticals has started a multi-center Phase Ib trial of its first-in-class Wnt-pathway-targeting antibody vantictumab (OMP-18R5) with docetaxel in non-small cell lung cancer (NSCLC). This trial is the second of three Phase Ib trials for vantictumab that OncoMed expects to initiate this year as part of the company’s collaboration with Bayer Pharma AG. The trial is a dose-escalation study of the anti-CSC antibody vantictumab in combination with docetaxel in patients with second...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters